Founder and Chief Scientific Officer, Mark Kiel, MD, Ph.D., was recently interviewed by Marnie Willman of Today’s Clinical Lab, resulting in an article called, 'When Your Data is Too Much to Process, Turn to AI/ML'. The Q&A session focused on the clinical diagnostic applications of artificial intelligence (AI) and machine learning (ML), and the unique challenges and solutions for incorporating AI/ML in a clinical lab.Of particular interest is the importance of human review in AI/ML systems. Mark also shared what technological developments in AI/ML he is most excited about and why. Check out this 5-minute read for insight into this hot topic.
“Explainability is a major point of focus for Genomenon because we work in an industry that impacts patients’ lives. We put emphasis on combining AI with expert review to ensure that all decisions are backed by sufficient evidence. “Explainability” means that you can understand how an AI model reached a certain decision, which is where that vital expert review comes into play.”
- Mark Kiel, MD, PhD
Explore & Discover!The Genomenon TeamAbout Genomenon
Genomenon is an AI-driven genomics company focused on making genomic information actionable for patients with rare genetic diseases and cancer. Keeping pace with the ever-evolving body of knowledge within genomics, Genomenon connects current research with patient DNA to accelerate clinical decision-making and pharmaceutical drug discovery.
Learn more about Genomenon at genomenon.com and follow them on LinkedIn and Twitter.
